Annual direct medical cost of active systemic lupus erythematosus in five European countries

Annals of the Rheumatic Diseases

Volumn 73, Issue 1, 2014, Pages 154-160

  Doria, Andrea ^a   Amoura, Zahir ^b   Cervera, Ricard ^c   Khamastha, Munther A ^d   Schneider, Matthias ^e   Richter, Jutta ^e   Guillemin, Francis ^f   Kobelt, Gisela ^g   Maurel, Frédérique ^h   Garofano, Anna ^h   Perna, Alessandra ⁱ   Murray, Miranda ⁱ   Schmitt, Claude ⁱ   Boucot, Isabelle ^j  

^a UNIVERSITY OF PADOVA   (Italy)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HOSPITAL CLÍNIC   (Spain)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL OF NANCY   (France)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h IQVIA   (United States)

ⁱ GLAXOSMITHKLINE   (United Kingdom)

^j GLAXOSMITHKLINE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FRANCE; GEOGRAPHIC DISTRIBUTION; GERMANY; HEALTH CARE COST; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTION; PRIORITY JOURNAL; RESOURCE MANAGEMENT; SPAIN; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT PLANNING; UNITED KINGDOM; VERY ELDERLY; YOUNG ADULT;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; DISEASE ACTIVITY; ECONOMIC EVALUATIONS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; FEMALE; FRANCE; GERMANY; GREAT BRITAIN; HEALTH EXPENDITURES; HEALTH RESOURCES; HUMANS; ITALY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPAIN;

EID: 84889686860     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202443     Document Type: Article

References (31)

1. Ruiz-Irastorza G, Khamashta MA, Castellino G, et al. Systemic lupus erythematosus. Lancet 2001;357:1027-32. (Pubitemid 32285401)
2. Doria A, Zen M, Canova M, et al. SLE diagnosis and treatment: when early is early. Autoimmun Rev 2010;10:55-60.
3. Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008;67:195-205. (Pubitemid 351183308)
4. Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010;69:2074-82.
5. Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010;69:1269-74.
6. Aringer M, Burkhardt H, Burmester GR, et al. Current state of evidence on 'off label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria, and Switzerland - a consensus report. Lupus 2012;21:386-401.
7. Van Vollenhoven RF. Rituximab - shadow, illusion or light? Autoimmun Rev 2012;11:563-7.
8. Panopalis P, Clarke AE. Systemic lupus erythematosus: clinical manifestations, treatment and economics. Expert Rev Pharmacoeconomics Outcomes Res 2006;6:563-75. (Pubitemid 44741606)
9. Lau CS, Mak A. The socioeconomic burden of SLE. Nat Rev Rheumatol 2009;5:400-4.
10. Zhu TY, Tam LS, Lee VW, et al. The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum 2009;61:1159-67.
11. Huscher D, Merkesdal S, Thiele K, et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006;65:1175-83. (Pubitemid 44277392)
12. Wilson EC, Jayne DR, Dellow E, et al. The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis. Rheumatology 2007;46:1096-101. (Pubitemid 47050611)
13. Zhu TY, Tam LS, Li EK. Cost of illness studies in systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken) 2011;63:751-60.
14. Clarke AE, Petri MA, Manzi S, et al. An international perspective on the well being and health care costs for patients with systemic lupus erythematosus. Tri-Nation Study Group. J Rheumatol 1999;26:1500-11. (Pubitemid 29317872)
15. Clarke AE, Petri M, Manzi S, et al. Tri-Nation Study Group. The systemic lupus erythematosus Tri-nation Study: absence of a link between health resource use and health outcome. Rheumatology (Oxford) 2004;43:1016-24. (Pubitemid 39144449)
16. Clarke AE, Panopalis P, Petri M, et al. SLE patients with renal damage incur higher health care costs. Rheumatology (Oxford) 2008;47:329-33. (Pubitemid 351267201)
17. Sutcliffe N, Clarke AE, Taylor R, et al. Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2001;40:37-47.
18. Slawsky KA, Fernandes AW, Fusfeld L, et al. A structured literature review of the direct costs of adult systemic lupus erythematosus in the US. Arthritis Care Res (Hoboken) 2011;63:1224-32.
19. Bombardieri C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
20. Gladman DD, Goldsmith CH, Urowitz MB, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000;27:373-6. (Pubitemid 30095466)
21. Petri M, Kim MY, Kalunian KC, et al. Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus. N Engl J Med 2005;353:2550-8. (Pubitemid 41785892)
22. Ow MY, Ho PC, Thumboo J, et al. Factors associated with health services utilization in patients with systemic lupus erythematosus: a systematic review. Clin Exp Rheumatol 2010;28:892-904.
23. Carls G, Li T, Panopalis P, et al. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. J Occup Environ Med 2009;51:66-79.
24. Panopalis P, Yazdany J, Gillis JZ, et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum 2008;59:1788-95.
25. Li T, Carls GS, Panopalis P, et al. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population. Arthritis Rheum 2009;61:755-63.
26. Aghdassi E, Zhang W, St-Pierre Y, et al. Healthcare cost and loss of productivity in a Canadian population of patients with and without lupus nephritis. J Rheumatol 2011;38:658-66.
27. Pelletier EM, Ogale S, Yu E, et al. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database. Clin Ther 2009;31:2653-4.
28. Zhu TY, Tam LS, Lee VW, et al. Systemic lupus erythematosus with neuropsychiatric manifestations incurs high direct costs: a cost-of-illness study in Hong Kong. Rheumatology (Oxford) 2009;48:564-8.
29. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006;77:918-26. (Pubitemid 44174075)
30. Doria A, Iaccarino L, Ghirardello A, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 2006;119:700-6. (Pubitemid 44128446)
31. Zen M, Bassi N, Nalotto L, et al. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin Exp Rheumatol Published Online First: 5 Jul 2012. PMID:22765883.